Chronic infusion of islet amyloid polypeptide causes anorexia in rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 271, Issue 6 40-6, 1996, Pages

  Arnelo, Urban ^a   Permert, Johan ^b   Adrian, Thomas E ^b   Larsson, Jörgen ^b   Westermark, Per ^b   Reidelberger, Roger D ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

appetite regulation; body weight; meal patterns; osmotic minipump; plasma levels; radioimmunoassay; satiety; subcutaneous administration; water intake

Indexed keywords

AMYLIN; WATER;

ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; FLUID INTAKE; FOOD INTAKE; INFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

EID: 0030458401     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.1996.271.6.r1654     Document Type: Article

References (34)

1. Arnelo, U., J. E. Blevins, J. Larsson, J. Permert, P. Westermark, R. D. Reidelberger, and T. E. Adrian. Effects of acute and chronic infusion of islet amyloid polypeptide on food intake in rats. Scand. J. Gastroenterol. 31: 83-89, 1996.
2. Balasubramaniam, A., V. Renugopalakrishnan, M. Stein, J. E. Fischer, and W. T. Chance. Syntheses, structures and anorectic effects of human and rat amylin. Peptides 12: 919-924, 1991.
3. Banks, W. A., A. J. Kastin, L. M. Maness, W. Huang, and J. B. Jaspan. Permeability of the blood-brain barrier to amylin. Life Sci. 57: 1993-2001, 1995.
4. Bouali, S. M., S. J. Wimalawansa, and F. B. Jolicoeur. In vivo central actions of rat amylin. Regul. Pept. 56: 167-174, 1995.
5. Bretherton-Watt, D., S. Gilbey, M. A. Ghatei, J. Beacham, and S. R. Bloom. Lack of effect of amylin amide on carbohydrate metabolism in man. Diabetologia 33: 115-117, 1990.
6. Butler, P. C., J. Chou, W. B. Carter, Y. N. Wang, B. H. Bu, D. Chang, J. K. Chang, and R. Rizza. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39: 752-756, 1990.
7. Chance, W. T., A. Balasubramaniam, A. Stallion, and J. E. Fischer. Anorexia following the systemic injection of amylin. Brain Res. 607: 185-188, 1993.
8. Chance, W. T., A. Balasubramaniam, F. S. Zhang, S. J. Wimalawansa, and J. E. Fischer. Anorexia following the intrahypothalamic administration of amylin. Brain Res. 539: 352-354, 1991.
9. Christmanson, L., P. Westermark, and C. Betsholtz. Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. Biochem. Biophys. Res. Commun. 205: 1226-1235, 1994.
10. Fürnsinn, C., P. Nowotny, M. Roden, M. Rohac, T. Pieber, S. Parzer, and W. Waldhäusl. Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcemia and fades during long-term exposure. Acta Endocrinol. 129: 360-365, 1993.
11. Hartter, E., T. Svoboda, B. Ludvik, M. Schuller, B. Lell, E. Kuenburg, M. Brunnbauer, W. Woloszczuk, and R. Prager. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34: 52-54, 1991.
12. Huang, H.-J. S., A. A. Young, J. E. Koda, O. L. Tulp, M. J. Johnson, and G. J. S. Cooper. Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension Dallas 19, Suppl. I: I-101-I-109, 1992.
13. Ingelfinger, F. J. The diagnosis of cancer of the pancreas. N. Engl. J. Med. 235: 653-661, 1946.
14. Jamal, H., D. Bretherton-Watt, K. Suda, M. A. Ghatei, and S. R. Bloom. Islet amyloid polypeptide-like immunoreactivity (amylin) in rats treated with dexamethasone and streptozotocin. J. Endocrinol. 126: 425-429, 1990.
15. Koda, J. E., M. Fineman, T. J. Rink, G. E. Dailey, D. B. Muchmore, and L. G. Linarelli. Amylin concentrations and glucose control. Lancet 339: 1179-1180, 1992.
16. Leighton, B., and G. J. S. Cooper. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature Lond. 335: 632-635, 1988.
17. Lukinius, A., E. Wilander, G. T. Westermark, U. Engström, and P. Westermark. Co-localization of islet amyloid polypeptide and insulin and the B cell secretory granules of the human pancreatic islets. Diabetologia 32: 240-244, 1989.
18. Lutz, T. A., E. Del Prete, and E. Scharrer. Reduction in food intake in rats by intraperitoneal injection of low doses of amylin. Physiol. Behav. 55: 891-895, 1994.
19. Lutz, T. A., E. Del Prete, and E. Scharrer. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 16: 457-462, 1995.
20. Morley, J. E., and J. F. Flood. Amylin decreases food intake in mice. Peptides 12: 865-869, 1991.
21. Morley, J. E., J. F. Flood, M. Horowitz, P. M. K. Morley, and M. J. Walter. Modulation of food intake by peripherally administered amylin. Am. J. Physiol. 267 (Regulatory Integrative Comp. Physiol. 36): R178-R184, 1994.
22. Morley, J. E., P. M. K. Morley, and J. F. Flood. Anorectic effects of amylin in rats over the life span. Pharmacol. Biochem. Behav. 44: 577-580, 1993.
23. Nakazato, M., J. Asai, K. Kangawa, S. Matsukura, and H. Matsuo. Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem. Biophys. Res. Commun. 164: 394-399, 1989.
24. Permert, J., J. Larsson, G. T. Westermark, M. K. Herrington, L. Christmansson, P. M. Pour, P. Westermark, and T. E. Adrian. Islet amyloid polypeptide in patients with pancreatic cancer patients and diabetes. N. Engl. J. Med. 330: 313-318, 1994.
25. Pieber, T. R., J. Roitelman, Y. Lee, K. L. Luskey, and D. T. Stein. Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity. Am. J. Physiol. 267 (Endocrinol. Metab. 30): E156-E164, 1994.
26. Pietschmann, P., K. H. Farsoudi, O. Hoffman, K. Klaushofer, and H. Hörandner. Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria. Bone 14: 167-172, 1993.
27. Sanke, T., Y. Hanabusa, C. Nakano, S. Okai, S. Nishimura, M. Hondo, and K. Nanjo. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 129-132, 1991.
28. Sexton, P. M., G. Paxinos, M. A. Kenney, P. J. Wookey, and K. Beaumont. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62: 553-567, 1994.
29. Sowa, R., T. Sanke, J. Hirayama, H. Tabata, H. Furata, S. Nishimura, and K. Nanjo. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 33: 118-120, 1990.
30. Wang, M.-W., P. Carlo, T. J. Rink, and A. A. Young. Amylin is more potent and more effective than glucagon in raising plasma glucose concentration in fasted anesthetized rats. Biochem. Biophys. Res. Commun. 181: 1288-1293, 1991.
31. Westermark, P., C. Wernstedt, E. Wilander, and K. Sletten. A novel peptide in the calcitonin gene related family as an amyloid fibril protein in the endocrine pancreas. Biochem. Biophys. Res. Commun. 140: 827-831, 1986.
32. Wimalawansa, S. J., R. D. Gunasekera, and H. K. Datta. Hypocalcemic actions of amylin amide in humans. J. Bone Miner. Res. 7: 1113-1116, 1992.
33. Young, A. A., G. J. S. Cooper, P. Carlo, T. J. Rink, and M.-W. Wang. Response to intravenous injections of amylin and glucagon in fasted, fed, and hypoglycemic rats. Am. J. Physiol. 264 (Endocrinol. Metab. 27): E943-E950, 1993.
34. Young, A. A., B. Gedulin, W. Vine, A. Percy, and T. J. Rink. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38: 642-648, 1995.